Tacrine
Tacrine is a cholinesterase inhibitor that was used as a medication for the treatment of Alzheimer's disease. It was the first drug approved by the Food and Drug Administration (FDA) for this purpose. Tacrine is known by its brand name, Cognex.
History[edit]
Tacrine was first synthesized in the 1940s and was initially investigated for its potential use in treating myasthenia gravis. However, it was not until the 1980s that its potential for treating Alzheimer's disease was explored. In 1993, Tacrine became the first drug approved by the FDA for the treatment of Alzheimer's disease.
Mechanism of Action[edit]
Tacrine works by inhibiting the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By preventing the breakdown of acetylcholine, Tacrine increases the levels of this neurotransmitter in the brain, which is thought to help alleviate some of the symptoms of Alzheimer's disease.
Pharmacokinetics[edit]
Tacrine is administered orally and is rapidly absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism in the liver, primarily by the enzyme cytochrome P450 1A2 (CYP1A2). The drug has a relatively short half-life, necessitating multiple doses throughout the day to maintain therapeutic levels.
Side Effects[edit]
The use of Tacrine is associated with several side effects, the most common of which are gastrointestinal disturbances such as nausea, vomiting, and diarrhea. More serious side effects include hepatotoxicity, which has limited its use. Regular monitoring of liver function tests is required for patients on Tacrine therapy.
Discontinuation[edit]
Due to its side effects and the development of newer cholinesterase inhibitors with better safety profiles, Tacrine has largely fallen out of favor and is no longer widely used. Other drugs such as donepezil, rivastigmine, and galantamine have largely replaced Tacrine in the treatment of Alzheimer's disease.
See Also[edit]
References[edit]
External Links[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian